✦ LIBER ✦

Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancer

✍ Scribed by Wallace Akerley; Howard Safran; Ken Zaner; Neal Ready; Tony Mega; Teresa Kennedy

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 74 KB
Volume: 107
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.22095

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of irinotecan, paclitaxel

Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma

✍ Mark A. Socinski; Alan B. Sandler; Valerie K. Israel; Heidi H. Gillenwater; Lang 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 1 views

## Abstract ## BACKGROUND This Phase II multicenter, open‐label, single‐arm study evaluated the efficacy and safety of a three‐drug combination of irinotecan (CPT‐11), paclitaxel, and carboplatin in advanced nonsmall cell lung carcinoma (NSCLC). ## METHODS Patients received repeated 21‐day cycle

Randomized phase II study of weekly doce

Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma

✍ Lee M. Krug; Vincent A. Miller; Jyoti Patel; John Crapanzano; Christopher G. Azz 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB 👁 1 views

Weekly paclitaxel and gemcitabine chemot

Weekly paclitaxel and gemcitabine chemotherapy for metastatic non-small cell lung carcinoma (NSCLC) : A dose-optimizing phase II trial

✍ Vera Hirsh; Renaud Whittom; Linda Ofiara; Pierre Desjardins; Joseph Ayoub; Danie 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB 👁 2 views

## Abstract ## BACKGROUND The current dose‐optimizing Phase II study evaluated the effect of weekly paclitaxel and gemcitabine on the response rate and survival of patients with non‐small cell lung carcinoma (NSCLC) using dose modifications that permitted optimal treatment intensity. ## METHODS

A Phase II trial of topotecan and gemcit

A Phase II trial of topotecan and gemcitabine in patients with previously treated, advanced nonsmall cell lung carcinoma

✍ David A. Rinaldi; Nancy A. Lormand; Joseph E. Brierre; James L. Cole; Brian C. B 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB 👁 2 views

## Abstract ## BACKGROUND Multiple trials have been performed to evaluate second‐line clinical chemotherapy in patients with advanced nonsmall cell lung carcinoma (NSCLC). However, no single agent or combination has demonstrated superior activity. ## METHODS Patients with advanced NSCLC who had

Phase II trial of weekly docetaxel in se

Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma

✍ Rogerio C. Lilenbaum; Michael A. Schwartz; Leonard Seigel; Francisco Belette; Ar 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB 👁 2 views

The authors thank Jim Herndon, Ph.D., for the statistical analysis and Ana Maria Gonzalez-Angulo, M.D., for article review and preparation.

Phase 2 trial of pemetrexed disodium and

Phase 2 trial of pemetrexed disodium and carboplatin in previously untreated extensive-stage small cell lung cancer, N0423

✍ Cheng E. Chee; James R. Jett; Albert M. Bernath Jr; Nathan R. Foster; Garth D. N 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB 👁 2 views